Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine for Suicidal Ideation in Major Depressive Disorder
NCT06891300Phase 3Recruiting
- Sponsor
- University of Ottawa Institute of Mental Health Research at The Royal
- Start
- Apr 2025
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ketamine in suicidal ideation and major depressive disorder (MDD), sponsored by University of Ottawa Institute of Mental Health Research at The Royal. Primary endpoint: Change in white matter microstructure. Started Apr 2025; status: recruiting.
02
Drugs
ketamine
03
Conditions
suicidal ideationmajor depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06891300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06891300.